The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma
Cholangiocarcinoma (CCA) is the most common biliary malignancy, and has a poor prognosis. The median overall survival with the standard-of-care chemotherapy (Gemcitabine and cisplatin) in patients with advanced-stage CCA is less than one year. The limited efficacy of chemotherapy or targeted therapy...
Main Authors: | Wen-Kuan Huang, Chun-Nan Yeh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/10/1396 |
Similar Items
-
The Role of microRNAs in Cholangiocarcinoma
by: Tingting Shi, et al.
Published: (2021-07-01) -
Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis
by: Sun C, et al.
Published: (2018-07-01) -
The role and mechanisms of action of microRNAs in cancer drug resistance
by: Wengong Si, et al.
Published: (2019-02-01) -
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report
by: Roberta Marciano, et al.
Published: (2017-09-01) -
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
by: Lu Zou, et al.
Published: (2021-07-01)